Summary of Key Information:

Reporting Period: Quarter ended June 30, 2026 (Q1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 of SEBI Listing Regulations

Audit Opinion:

Clean/Unmodified conclusion on both standalone and consolidated financial results by Deloitte Haskins & Sells LLP

Key Financial Highlights [INR in million]:

Consolidated Results:

Revenue from Operations: ₹7,977 (Q1 FY27) vs ₹6,698 (Q1 FY26) - 19.1% YoY growth

Total Income: ₹8,296 (Q1 FY27) vs ₹6,979 (Q1 FY26) - 18.9% YoY growth

Profit before tax: ₹2,287 (Q1 FY27) vs ₹1,811 (Q1 FY26) - 26.3% YoY growth

Profit for the period: ₹1,705 (Q1 FY27) vs ₹1,340 (Q1 FY26) - 27.2% YoY growth

EPS (Basic): ₹10.15 (Q1 FY27) vs ₹7.94 (Q1 FY26)

EPS (Diluted): ₹10.13 (Q1 FY27) vs ₹7.93 (Q1 FY26)

Other Equity: ₹23,406 (as of March 31, 2026)

Standalone Results:

Revenue from Operations: ₹7,644 (Q1 FY27) vs ₹6,407 (Q1 FY26) - 19.3% YoY growth

Total Income: ₹7,943 (Q1 FY27) vs ₹6,670 (Q1 FY26) - 19.1% YoY growth

Profit before tax: ₹2,223 (Q1 FY27) vs ₹1,724 (Q1 FY26) - 28.9% YoY growth

Profit for the period: ₹1,659 (Q1 FY27) vs ₹1,293 (Q1 FY26) - 28.3% YoY growth

EPS (Basic): ₹9.94 (Q1 FY27) vs ₹7.76 (Q1 FY26)

EPS (Diluted): ₹9.92 (Q1 FY27) vs ₹7.74 (Q1 FY26)

Other Equity: ₹23,053 (as of March 31, 2026)

Segment-wise Performance:

No reportable segments identified as the CODM evaluates performance as a single unit

Corporate Actions:

Interim Dividend: Approved ₹5 per equity share (50% on face value of ₹10 each) for FY 2026-27

Record Date: July 30, 2026

Dividend Payment: Within 30 days of declaration

Final Dividend: Proposed ₹4 per equity share for FY 2025-26 (subject to shareholder approval)

Other Significant Information:

Acquisitions:

1. Dr. Lal PathLabs FZCO (Dubai subsidiary) approved acquisition of 80% stake in Sunshine Healthcare Limited, Ghana for up to GHS 45.6 million (₹380 million)

  • Healthcare/Diagnostics business
  • Incorporated September 7, 2010
  • Transaction expected to complete by August 31, 2026

2. Dr. Lal Ventures Private Limited approved subscription of 30% stake in Neuome Technologies Private Limited for up to ₹35 million

  • Develops innovative solutions in sample preservation, pre-analytical technologies and bio-banking
  • Incorporated April 16, 2020
  • Transaction expected to complete by August 31, 2026

Previous Acquisitions:

Acquired 100% stake in Shahbazkers Diagnostic Centre Private Limited on May 1, 2026 for ₹200 million cash consideration

Goodwill generated: ₹143 million

ESOP Grants:

Granted 119,300 stock options under Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025

Exercise price at face value of share on grant date

Vesting period: 1-4 years from grant date

Exercise period: 5 years from vesting

Capital Changes:

Issued 82,750 equity shares to Dr. Lal PathLabs Employee Welfare Trust under ESOP Plan 2022

Made further investment of ₹77.5 million in Dr. Lal Ventures Private Limited

Bonus shares issued in December 2025 in 1:1 ratio (8,377,551 shares)

Exceptional Items:

Impact of Labour Codes: ₹301 million recognized in FY 2025-26 as exceptional item [Non-Recurring]

Subsidiary Entities Included in Consolidation:

1. Dr. Lal PathLabs Limited (Parent)

2. Paliwal Diagnostics Private Limited

3. Dr. Lal PathLabs Nepal Private Limited

4. Dr. Lal PathLabs Bangladesh Private Limited

5. Dr. Lal Ventures Private Limited

6. PathLabs Unifiers Private Limited

7. Shahbazkers Diagnostic Centre Private Limited (w.e.f. May 1, 2026)

8. Dr. Lal Pathlabs FZCO (w.e.f. June 12, 2026)

9. Centrapath Labs Private Limited (step-down)

10. APRL PathLabs Private Limited (step-down)

11. Chanre Laboratory Private Limited (step-down)